It utilized its patented safflower pharming platform to develop and make proteins and oils for the nutraceutical, functional food and beverage, and pharmaceutical industries.
Its lead pharmaceutical products under development were biosimilar insulin and Apo AI(Milano).
In October 2009, Botaneco merged with Quebec City-based Advitech, a health sciences and technology company.
[5] Upon government approval, a new company called Tasly-SemBioSys Bio-Pharmaceuticals Co., Ltd. was incorporated in Tianjin, China.
The new company was structured as a Sino-Foreign Equity Joint Venture and seeks to develop and commercialize a variety of products including pharmaceutical, functional foods, and nutraceuticals for China and the world.